Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Intangible assets

v3.22.1
Intangible assets
 12 Months Ended
Dec. 31, 2021
Disclosure of detailed information about intangible assets [abstract]  
Intangible assets

 

10. Intangible assets

 

   

Software

£

    

Patent and

licence costs

£

    

Total

£

  
Cost                        
At January 1, 2020     36,380       308,016       344,396  
Additions     13,233       156,865       170,098  
At December 31, 2020     49,613       464,881       514,494  
Additions     -       123,191       123,191  
At December 31, 2021     49,613       588,072       637,685  
                         
Amortization                        
At January 1, 2020     9,433       29,335       38,768  
Charge for the year     13,582       38,307       51,889  
At December 31, 2020     23,015       67,642       90,657  
Charge for the year     16,521       46,930       63,451  
At December 31, 2021     39,536       114,572       154,108  
                         
Net book value                        
At December 31, 2021     10,077       473,500       483,577  
                         
At December 31, 2020     26,598       397,239       423,837  

 

The amortization charge for the year is recognized within research and development costs in the statements of comprehensive loss.

 

 

TC BIOPHARM (HOLDINGS) PLC

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)